Michael Maestre is a Principal Scientist at Iambic Therapeutics, leading biochemistry and enzymology efforts in small molecule oncology drug discovery since September 2022. Prior experience includes a role as Scientist III at Eurofins Discovery, where technical and scientific support for KINOMEscan studies was provided from March 2021 to August 2022. During a nine-year tenure at Pfizer from October 2012 to March 2021, Michael developed kinase screening assays and contributed to structure-based drug design. Previous positions include Senior Associate Scientist at La Jolla Institute for Allergy and Immunology and Research Technician II, along with a research internship at San Diego State University and a master's thesis project at New York University. Academic qualifications include a Master of Science in Biology from New York University and a Bachelor of Arts in Biology from Boston University.
This person is not in any teams
This person is not in any offices